

**Improving the Care of Patients with Persistent Hypercholesterolemia by
Decreasing Cardiovascular Risk Using PCSK9 Inhibitors: A
Comprehensive Infographic View**

TOOLKIT

Websites and Additional Reading

Resource	Web Address
CDC. Cholesterol.	https://www.cdc.gov/cholesterol/facts.htm
NIH. US National Library of Medicine. Genetics Home Reference. Hypercholesterolemia.	https://ghr.nlm.nih.gov/condition/hypercholesterolemia
NIH. US National Library of Medicine. Medline Plus. High Blood Cholesterol Levels.	https://medlineplus.gov/ency/article/000403.htm
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. (Grundy SM, et al. <i>J Am Coll Cardiol.</i> 2019;73(24):e285-e350)	https://www.ncbi.nlm.nih.gov/pubmed/30423393
PCSK9 inhibitors for prevention of atherosclerotic cardiovascular disease. (Bittner VA, Giugliano RP, Brinton EA, Guyton JR. <i>J Clin Lipidol.</i> 2018;12:835-843)	https://www.ncbi.nlm.nih.gov/pubmed/30055750
Recent Updates on the Use of PCSK9 Inhibitors in Patients with Atherosclerotic Cardiovascular Disease. (Dixon DJ, et al. <i>Curr Atheroscler Rep.</i> 2019;21(5):16)	https://www.ncbi.nlm.nih.gov/pubmed/30877491
Evolocumab and clinical outcomes in patients with cardiovascular disease. (Sabatine MS, et al. <i>N Engl J Med.</i> 2017;376:1713-1722)	https://www.ncbi.nlm.nih.gov/pubmed/28304224
Alirocumab and cardiovascular outcomes after acute coronary syndrome. (Schwartz GG, et al. <i>N Engl J Med.</i> 2018;379:2097-2107)	https://www.ncbi.nlm.nih.gov/pubmed/30403574
Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges. (Sampson UK, Fazio S, Linton MF. <i>Curr Atheroscler Rep.</i> 2012;14:1-10)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3697085/

Selected Ongoing Clinical Trials

Resource	Address
An Extension Trial of Inclisiran Compared to Evolocumab in Participants With Cardiovascular Disease and High Cholesterol NCT03060577	https://clinicaltrials.gov/ct2/show/NCT03060577?term=pcsk9&recrs=ad&cond=hypercholesterolemia&rank=7
Study of Evinacumab (REGN1500) in Participants With Persistent Hypercholesterolemia NCT03175367	https://clinicaltrials.gov/ct2/show/NCT03175367?term=pcsk9&recrs=ad&cond=hypercholesterolemia&draw=2&rank=12
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension (FOURIER OLE) NCT02867813	https://clinicaltrials.gov/ct2/show/NCT02867813?term=pcsk9&recrs=ad&cond=hypercholesterolemia&draw=1&rank=19
Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo NCT02957682	https://clinicaltrials.gov/ct2/show/NCT02957682?term=alirocumab&recrs=abd&cond=hypercholesterolemia&rank=4

Resources for Clinicians and Patients

Resource	Address
American College of Cardiology	https://www.acc.org/search#q=Hypercholesterolemia&sort=relevancy
American Heart Association. Prevention and Treatment of High Cholesterol (Hyperlipidemia).	https://www.heart.org/en/health-topics/cholesterol/prevention-and-treatment-of-high-cholesterol-hyperlipidemia
CDC. Cholesterol Patient Education Handouts.	https://www.cdc.gov/cholesterol/materials_for_patients.htm
NIH. National Heart, Lung, and Blood Institute. High Blood Cholesterol.	https://www.nhlbi.nih.gov/health-topics/high-blood-cholesterol
National Lipid Association (NLA). An educational booklet for patients with familial hypercholesterolemia.	http://nlaresourcecenter.lipidjournal.com/Content/PDFs/FA-Patient-Book-English.pdf